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Abstract
Background Modular endoprostheses are commonly used
to reconstruct defects of the distal femur and proximal tibia
after bone tumor resection. Because limb salvage surgery
for bone sarcomas is relatively new, becoming more fre-
quently used since the 1980s, studies focusing on the long-
term results of such prostheses in treatment of primary
tumors are scarce.
Questions/purposes (1) What proportion of patients
experience a mechanical complication with the
MUTARS1 modular endoprosthesis when used for tumor
reconstruction around the knee, and what factors may be
associated with mechanical failure? (2) What are the
nonmechanical complications? (3) What are the implant
failure rates at 5, 10, and 15 years? (4) How often is limb
salvage achieved using this prosthesis?
Methods Between 1995 and 2010, endoprostheses were
the preferred method of reconstruction after resection of
the knee in adolescents and adults in our centers. During
that period, we performed 114 MUTARS1 knee replace-
ments in 105 patients; no other endoprosthetic systems
were used. Four patients (four of 105 [4%]) were lost to
followup, leaving 110 reconstructions in 101 patients for
review. The reverse Kaplan-Meier method was used to
calculate median followup, which was equal to 8.9 years
(95% confidence interval [CI], 8.0–9.7). Mean age at sur-
gery was 36 years (range, 13–82 years). Predominant
diagnoses were osteosarcoma (n = 56 [55%]),
leiomyosarcoma of bone (n = 10 [10%]), and chondrosar-
coma (n = 9 [9%]). In the early period of our study, we
routinely used uncemented uncoated implants for primary
reconstructions. Later, hydroxyapatite (HA)-coated
implants were the standard. Eighty-nine reconstructions
(89 of 110 [81%]) were distal femoral replacements (78
uncemented [78 of 89 {88%}, 42 of which were HA-coated
[42 of 78 {54%}]) and 21 (21 of 110 [19%]) were proximal
tibial replacements. In 26 reconstructions (26 of 110
[24%]), the reconstruction was performed for a failed
previous reconstruction. We used a competing risk model
to estimate the cumulative incidence of implant failure.
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Results Complications of soft tissue or instability occur-
red in seven reconstructions (seven of 110 [6%]). With the
numbers we had, for uncemented distal femoral replace-
ments, we could not detect a difference in loosening
between revision (five of 17 [29%]) and primary recon-
structions (eight of 61 [13%]) (hazard ratio [HR], 1.72;
95% CI, 0.55–5.38; p = 0.354). Hydroxyapatite-coated
uncemented implants had a lower risk of loosening (two of
42 [5%]) than uncoated uncemented implants (11 of 36
[31%]) (HR, 0.23; 95% CI, 0.05–1.06; p = 0.060). Struc-
tural complications occurred in 15 reconstructions (15 of
110 [14%]). Infections occurred in 14 reconstructions (14
of 110 [13%]). Ten patients had a local recurrence (10 of
101 [10%]). With failure for mechanical reasons as the
endpoint, the cumulative incidences of implant failure at 5,
10, and 15 years were 16.9% (95% CI, 9.6–24.2), 20.7%
(95% CI, 12.5–28.8%), and 37.9% (95% CI, 16.1–59.7),
respectively. We were able to salvage some of the failures
so that at followup, 90 patients (90 of 101 [89%]) had a
MUTARS1 in situ.
Conclusions Although no system has yet proved ideal to
restore normal function and demonstrate long-term reten-
tion of the implant, MUTARS1 modular endoprostheses
represent a reliable long-term option for knee replacement
after tumor resection, which seems to be comparable to
other modular implants available to surgeons. Although the
number of patients is relatively small, we could demon-
strate that with this prosthesis, an uncemented HA-coated
implant is useful in achieving durable fixation.
Level of Evidence Level IV, therapeutic study.
Introduction
Various techniques have been described for management
of reconstruction of malignant tumors about the knee in
adults, including implantation of osteoarticular allografts
[25, 34], allograft-prosthetic composites [10, 23] and cus-
tom-made [26, 27] or modular [13, 28] endoprotheses.
Endoprosthetic reconstruction likely is the most commonly
used approach, in part as a result of the ease of use com-
pared with other options and the difficulty of obtaining
allografts in some centers in addition to the reported risks
of nonunion, fracture, and infection [6, 26, 27]. Potential
advantages of endoprostheses include their relative avail-
ability, immediate stability, the possibility of rapid
recovery, and early weightbearing [26]. Compared with
custom-made implants, modular endoprostheses provide
the ability to adjust the proper length at the time of the
reconstruction [7].
Nevertheless, revisions of endoprosthetic reconstruc-
tions occur frequently. Infection, occurring in 6% to 20%
of patients, is the leading cause of failure in the early years
after surgery [2, 15, 22, 26–28, 32]. In the longer term,
mechanical complications are the main concern, most
notably aseptic loosening, periprosthetic fractures, and
wear [13, 17, 19]. Because the survival of patients with
bone sarcomas has improved, and most patients with pri-
mary bone tumors are young and active and place high
demands on their implants, improving implant designs and
reconstructive techniques are essential to reduce the risk of
mechanical complications [26]. The MUTARS1 system
(Modular Universal Tumor And Revision System;
implantcast, Buxtehude, Germany; FDA approval pending)
was introduced in 1992 and has since been widely used in
Europe, Australia, and various Asian countries; results of
its use in both orthopaedic oncology and revision surgery
have been documented [12, 13, 16]. To our knowledge, no
studies have evaluated the intermediate- to long-term
results of the MUTARS1 knee replacement system in
primary tumor reconstructions and revision procedures.
We therefore asked: (1) What proportion of patients
experience a mechanical complication with the
MUTARS1 modular endoprosthesis when used for tumor
reconstruction around the knee, and what factors may be
associated with mechanical failure? (2) What are the
nonmechanical complications? (3) What is the cumulative
incidence of implant failure at 5, 10, and 15 years? (4) How
often is limb salvage achieved using this prosthesis?
Patients and Methods
We present a retrospective case series of all patients with a
primary malignant or aggressive benign bone or soft tissue
tumor in whom a MUTARS1 distal femoral or proximal
tibial replacement was performed for primary reconstruc-
tion or for revision of a failed previous reconstruction.
Institutional databases were searched to identify patients
who had MUTARS reconstruction between 1995 and 2010
with a minimum followup of 5 years. During the early
period under study, we performed a limited number of
osteoarticular allograft reconstructions, mainly in young
patients. In case it was possible to save adjacent joints, we
preferred to perform an intercalary resection and recon-
structed the defect with an allograft [5, 6]. Generally
speaking, endoprosthetic reconstruction was the preferred
method of reconstruction when resection of the knee was
deemed inevitable in adolescents and adults. No other
endoprosthetic systems have been used in our centers. We
performed a total of 114 MUTARS1 reconstructions about
the knee during the period in question in 105 patients. Four
patients (four of 105 [4%]) were lost to followup, leaving
110 reconstructions in 101 patients for review; of these, 64
(64 of 101 [63%]) were alive at final review. The reverse
Kaplan-Meier method was used to calculate the median
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followup, which was equal to 8.9 years (95% confidence
interval [CI], 8.0–9.7) (Table 1).
All diagnoses were proven histologically before opera-
tion. The feasibility of limb-salvaging resection was
evaluated on MRI. In the case of suspected joint involve-
ment, an extraarticular resection was performed removing
the joint en bloc with the patella cut in the coronal plane.
Of 84 implants (84 of 110 [76%]) that were implanted for
primary reconstruction after tumor resection, 39 (46%) had
an extraarticular resection. Twenty-six implants (26 of 110
[24%]) were implanted as a revision of a failed recon-
struction, including nine MUTARS1 and 17 other
reconstructions (Table 2).
A lateral or medial parapatellar approach was used; this
depended on the location of the tumor and biopsy tract,
which was excised in continuity with the tumor. In all cases,
we used a rotating hinged MUTARS1 distal femoral or
proximal tibial replacement. A polyethylene locking mech-
anism connected the femoral and tibial components. Until
March 2003, we used the conventional polyethylene lock.
From then onward, the PEEK-OPTIMA1 (Invibio Ltd,
Thornton-Cleveleys, UK) lock was used. Extension of the
implant was possible in 20-mm increments. All stems and
extension pieces were equipped with sawteeth at the junc-
tions to allow rotational adjustment in 5 increments. The
hexagonally shaped stems were available for uncemented
(TiAl6V4) or cemented (CoCrMo) fixation. Femoral stems
were curved to match the natural anterior curvature of the
femoral diaphysis. We generally preferred uncemented fix-
ation, unless we were unable to obtain adequate press-fitting
or in cases in which bone quality was deemed insufficient
for uncemented fixation. In the early period under study, we
routinely used uncemented uncoated implants because at
that time, the MUTARS1 system did not come with
hydroxyapatite (HA)-coated stems standardly; HA-coated
stems were mainly used in cases with a presumed higher risk
of loosening such as patients with a failed previous recon-
struction. Later, HA-coated implants were the standard for
primary reconstruction. The medullary cavity was reamed
with a hexagonal rasp to secure optimal contact between the
bone and implant. In case of uncemented fixation, the
medullary cavity was underreamed by 1 mm. In case of
cemented fixation, we overreamed the canal for 2 mm and
third-generation cementing techniques were used.
In cases in which an extensor mechanism reconstruction
had to be performed, we ran nonabsorbable sutures through
the designated holes in the tibial component to fix an
attachment tube (implantcast) to the implant; the extensor
mechanism was later attached to the tube, again using
nonabsorbable sutures. After assemblage of the prosthesis,
a trial reduction was performed. A final check was per-
formed to assess knee motion and soft tissue tension and
subsequently, the implant was locked.
All patients received prophylactic intravenous cepha-
losporins before surgery; these were continued for 1 to 5
days. Drains were removed after a maximum of 48 hours.
Table 1. Study data








Leiomyosarcoma of bone 10 10
Chondrosarcoma 9 9
Giant cell tumor of bone 8 8
Pleomorphic undifferentiated sarcoma 7 7
Ewing sarcoma 5 5
Low-grade osteosarcoma 2 2
Sarcoma not otherwise specified 2 2
Synovial sarcoma 1 1
Diffuse-type giant cell tumor 1 1
Reconstruction site
Distal femur 89 81
Proximal tibia 21 19
Neoadjuvant and adjuvant therapies (around
implantation of MUTARS1)
Neoadjuvant chemotherapy 61 60
Adjuvant chemotherapy 64 63
Neoadjuvant radiotherapy 2 2





PEEK-OPTIMA1 locking mechanism 71 65
Extensor reconstruction 19 17
MUTARS1 attachment tube used 16 15
Complications
Type I (soft tissue, instability) 7 6
Type II (aseptic loosening) 17 16
Type III (structural) 15 14
Type IV (infection) 14 13
Type V (tumor progression) 10 10
Failure
Any type of revision, including refixation 40 36
Major revision/removal entire prosthesis 27 25
Status at final followup
No evidence of disease 64 63
Alive with disease – –
Died of disease 34 34
Died of other cause 3 3
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Based on pain, patients were mobilized under supervision
of a physical therapist, usually on the first postoperative
day. Antithrombotic prophylaxis was given until 6 weeks
postoperatively.
Patients were followed during outpatient visits at 2 and 6
weeks after discharge, after 3 and 6 months, and every 6
months thereafter. Radiographic followup consisted of
conventional radiographs and additional imaging (CT/
MRI) if complications or recurrence were suspected.
Complications and failures were recorded and classified
according to Henderson et al. [17, 18]. Aseptic loosening
was defined as migration of the prosthesis on imaging
(periprosthetic lucency on conventional radiographs or CT
scan or halo formation on CT) in the absence of infection.
We however chose to report on the clinical rather than
radiological loosening, ie, those that required revision,
partly because it can be hard to determine which cases are
at risk for future failure/loosening, and it is therefore dif-
ficult to reliably comment on the occurrence and
significance of these signs. Radiographic signs alone were
not observed as a reason for implant failure. Rates of
aseptic loosening were compared between primary and
revision reconstructions (arthroscopy, curettage, and con-
ventional TKA were not considered as previous
reconstructions). Periprosthetic and prosthetic fractures
were diagnosed on imaging or intraoperatively. Infection
was defined as any deep (periprosthetic) infectious process
diagnosed through physical examination, imaging, labora-
tory tests (including C-reactive protein, erythrocyte
sedimentation rate, and synovial fluid leukocyte count) and
microbiologic cultures.
Statistical Analysis
All data were complete. To estimate the cumulative inci-
dence of revision for different types of failure, a competing
risks model was used with patient mortality as a competing
event [20, 30]. Failures were defined as removal of part of
or all of the implant, major revision (exchange of the
femoral component, tibial component, or the locking
mechanism), or cemented refixation as the endpoint. Fail-
ure did not include isolated revision of the bushing. The
influence of potential risk factors on the cumulative inci-
dence of revision was determined with Cox regression
analyses. SPSS 21.0 (IBM Corp, Armonk, NY, USA) was
used for statistical analysis (level of significance, p \
0.050). All analyses for the competing risk models have
been performed with the mstate library [9] in the R soft-
ware package [31].
Mean age at surgery was 36 years (range, 13–82 years).
Predominant diagnoses were osteosarcoma (n = 56 [55%]),
leiomyosarcoma of bone (n = 10 [10%]), chondrosarcoma
(n = 9 [9%]), giant cell tumor of bone (n = 8 [8%]), and
pleomorphic undifferentiated sarcoma (n = 7 [7%]). Sixty-
four patients (64 of 101 [63%]) were treated with
chemotherapy (according to appropriate protocols) around
the period of MUTARS1 implantation and four (four of
101 [4%]) underwent radiotherapy.
Eighty-nine reconstructions (81%) were distal femoral
replacements and 21 (19%) were proximal tibial replace-
ments. Eleven distal femoral replacements (11 of 89
[12%]) had a cemented femoral stem. Of 78 uncemented
distal femoral replacements (78 of 89 [88%]), 42 were HA-
coated (42 of 78 [54%]). All proximal tibial replacements
had an uncemented tibial stem, 12 of which were HA-
coated (12 of 19 [57%]) (Fig. 1A–B); one (one of 21 [5%])
had a cemented femoral stem. Patellar components were
used in 37 distal femoral replacements (37 of 89 [42%])
and in three proximal tibial replacements (three of 21
[14%]). Median total resection length was 16 cm (range,
12–30 cm) for distal femoral replacements and 14 cm
(range, 12–26 cm) for proximal tibial replacements.
Attachment tubes were used in 14 proximal tibial
replacements (14 of 21 [67%]) and in two distal femoral
replacements (two of 89 [2%]). An extensor reconstruction
Table 2. Procedures performed before implantation of the primary MUTARS1, subsequent reconstructions, and reasons for failure
Procedure Reconstruction Number Reason(s) for reconstruction failure
En bloc resection Allograft-prosthetic composite 6 Allograft collapse (n = 2), allograft fracture (n = 2),
nonunion (n = 1), infection (n = 1)
Kotz prosthesis 4 Prosthetic fracture (n = 2), loosening (n = 1), infection (n = 1)
Intercalary allograft 3 Nonunion (n = 2), allograft fracture (n = 1)
Osteoarticular allograft 2 Allograft fracture
Extracorporeally radiated autograft 1 Resorption
Inlay allograft 1 Recurrence
Curettage Cancellous bone grafting 5 Recurrence
Cement 3 Recurrence
Arthroplasty TKA 1 –
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was performed in 11 proximal tibial replacements (11 of 21
[58%]) and six distal femoral replacements (six of 89
[7%]). Rotation of a gastrocnemius muscle flap was per-
formed in four proximal tibial replacements (four of 21
[19%], in one case combined with a split skin graft).
Allogeneic fascia lata were used in six distal femoral
replacements (six of 89 [7%]) and in two proximal tibial
replacements (two of 21 [10%]). Three implants (three of
110 [3%]) were silver-coated.
During tumor resection, clear surgical margins were
obtained in 95 patients (95 of 101 [94%]). Two patients
(two of 101 [2%]) with giant cell tumors had intentional




Complications of soft tissue or instability (Henderson Type
1) occurred in seven reconstructions (seven of 110 [6%],
six distal femoral replacements, one proximal tibial
replacement) after a median of 5 months (range, 0–46
months). These complications included skin necrosis (n = 2
[two of 110 {2%}]), flexion contracture (n = 2 [two of 110
{2%}]), and patellar dislocation (n = 1 [one of 110 {1%}]).
One patient underwent surgery for extensor mechanism
insufficiency (n = 1 [one of 110 {1%}]). We could not
identify factors associated with the occurrence of Type 1
complications. No Type 1 complication resulted in removal
or revision of the prosthesis.
Aseptic loosening (Henderson Type 2) occurred in 15
distal femoral replacements (15 of 89 [17%]) and two
proximal tibial replacements (two of 21 [10%]) after a
median of 1.2 years (range, 0.5–15 years). Both proximal
tibial replacements had loosening of the femoral compo-
nent (both uncemented, one HA-coated), for which
cemented refixation was undertaken. Of the 15 distal
femoral replacements, nine had loosening of the femoral
component, three of the tibial component, and three of both
components. Treatment consisted of cemented refixation (n
= 6), uncemented revision of the femoral component (n =
4), cemented revision (n = 4), and a total femoral
replacement (as a result of poor remnant host bone) (n = 1).
With the numbers we had, for uncemented distal femoral
replacements, we could not detect an association between
reconstruction length and the rate of loosening (hazard
ratio [HR], 1.06; 95% CI, 0.93–1.21; p = 0.393) nor a
difference in loosening between revision (five of 17 [29%])
and primary reconstructions (eight of 61 [13%]) (HR, 1.72;
95% CI, 0.55–5.38; p = 0.354). Uncemented HA-coated
distal femoral replacements had a lower risk of loosening
(two of 42 [5%]) than uncemented uncoated implants (11
of 36 [31%]) (HR, 0.23; 95% CI, 0.05–1.06; p = 0.060)
(Fig. 2).
Fig. 1A–B Conventional AP (A) and lateral (B) radiographs taken 6
years after extraarticular resection for an osteosarcoma of the distal
femur in a 46-year-old female patient. The defect was reconstructed
with an uncemented HA-coated MUTARS1 distal femoral replace-
ment with a PEEK-OPTIMA1 locking mechanism. The postoperative
course was uncomplicated and no further procedures were
undertaken.
Fig. 2 Kaplan-Meier curve showing survival to the occurrence of
loosening for uncemented uncoated (blue line, n = 36) and
uncemented HA-coated (green line, n = 42) distal femoral
replacements.
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Structural complications (Henderson Type 3) occurred
in 15 reconstructions (15 of 110 [14%]) after a mean of 3
years (range, 0.0–13.5 years). These included six compli-
cations of the locking mechanism: three fractures, two
instances of wear, and one unlocking of the locking
mechanism. Four occurred in PEEK-OPTIMA1 locks.
There were four periprosthetic fractures occurring at 3
weeks, 8 months, 20 months, and 6 years, respectively.
There were three fractures of the femoral component, two
with a 12-mm core diameter and a defect of 17.5 and 21.5
cm and one with a 16-mm core diameter stem with a defect
of 15.5 cm. These stem fractures occurred 2, 4, and 4 years,
respectively. There was one fractured insert and one
implant rotation deformity.
Two prosthetic fractures and one periprosthetic fracture
resulted in revision or removal of the entire implant; others
were managed either conservatively or with limited revi-
sion procedures such as fixation of the periprosthetic
fracture with a small plate, relocking of the locking
mechanism, or revision of the locking mechanism. In
addition, undisplaced fissure fractures occurred during
implantation in 11 reconstructions: nine distal femoral
replacements and two proximal tibial replacements. All
healed uneventfully. Replacement of the bushings was
performed in nine reconstructions (nine of 110 [8%]) after
a mean of 6 years (range, 0.1–18 years).
Nonmechanical Complications
Deep infections (Henderson Type 4) occurred in 15
reconstructions (15 of 110 [14%]). According to the Hen-
derson classification, nine infections were early (\2 years
after implantation [nine of 110 {8%}]) and six were late
(six of 110 [5%]). Three early-infected implants were
retained. Three late infections occurred after operative
intervention for another complication; of these, two were
retained.
Local recurrences (Henderson Type 5) occurred in 10
patients (10 of 101 [10%]) after a mean of 2 years (range,
0.8–6 years). All patients who developed a local recurrence
had clear surgical margins during the index resection. Two
patients had received radiotherapy (one leiomyosarcoma,
one high-grade osteosarcoma of an unusual subtype).
Treatment consisted of ablative surgery in seven patients
and of a second limb-salvaging resection (without remov-
ing the implant) in two. In one patient no further treatment
was undertaken as a result of a poor prognosis. Focusing on
patients without prior resections, local recurrences occur-
red in five of 39 patients with an extraarticular resection
(13%) and in four of 45 patients with an intraarticular
resection (9%) (p = 0.561).
Implant Failure Rates
With failure for mechanical reasons (Types 1–3) as the
endpoint, the cumulative incidences of implant failure at 5,
10, and 15 years were 16.9% (95% CI, 9.6–24.2), 20.7%
(95% CI, 12.5–28.8), and 37.9% (95% CI, 16.1–59.7),
respectively (Fig. 3). With failure for infection (Type 4) as
the endpoint, these were 7.9% (95% CI, 2.7–13.2), 10.0%
(95% CI, 3.5–16.4), and 10.0% (95% CI, 3.5–16.4),
respectively. With failure from tumor progression (Type 5)
as the endpoint, these were 5.0% (95% CI, 0.7–9.2), 6.2%
(95% CI, 1.4–11.0), and 6.2% (95% CI, 1.4–11.0),
respectively . None of the assessed variables (extraarticular
resection, HA coating of uncemented implants, recon-
struction length of[16 cm, adjuvant therapy, or having a
preceding reconstruction) was found to have been associ-
ated with differences in implant survival in univariable Cox
regression analyses.
Limb Salvage
Limb salvage was achieved in 91 patients (90%). In total,
64 of 101 patients had their original MUTARS1 in situ
without refixation, partial revision, or major revision/re-
moval of the implant. Not all failures required a second
MUTARS1 because some cases of failure were managed
while the same implant was in place (for example the cases
of loosening that were managed with cemented refixation
of the implant or failure of the locking mechanism, which
was managed with revision of the polyethylene lock). In
all, 55 patients (55 of 101 [55%]) required a total of 141
Fig. 3 Competing-risk analyses of implant failure. This plot shows
the cumulative incidence of mechanical failure (Type 1–3), infection
(Type 4), and tumor progression (Type 5). Patient mortality was used
as a competing event in these analyses.
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further surgical procedures: 78 (78 of 141 [55%]) for
infection and 42 (42 of 141 [30%]) for mechanical reasons.
At review, 90 patients (90 of 101 [89%]) had a MUTARS1
in situ. Above-knee amputations were undertaken in seven
patients (seven of 101 [7%]; five as a result of a local
recurrence, two resulting from infection), rotationplasty in
two (two of 101 [2%]; one as a result of local recurrence,
one resulting from infection), total femoral replacement in
one (one of 101 [1%], as a result of loosening and poor
remnant host bone), and knee disarticulation in one (as a
result of a periprosthetic fracture).
Discussion
Modular endoprostheses are frequently used to reconstruct
skeletal and knee defects created by resecting a bone neo-
plasm from the distal femur or proximal tibia. However,
they are associated with substantial complication rates on
both the short and long term, most notably infection and
aseptic loosening [19, 26, 27]. We sought to evaluate the
long-term results of knee arthroplasty with MUTARS1
modular endoprostheses in the treatment of primary tumors,
emphasizing on mechanical complications.
Our study has a number of limitations. Preferably, one
would report on proximal tibial and distal femoral
replacements separately because they may differ in the
types of complications by site. However, we were ham-
pered by a limited number of patients and we therefore
chose to report on knee arthroplasty as one group. We
grouped patients who had a previous reconstruction toge-
ther with those reconstructions done for a primary resection
and these groups are disparate, which might have influ-
enced our overall risk of loosening. However, we feel that
the results as now presented best describe our clinical
experiences with this implant system during the period
under study. Moreover, as a result of the long retrospective
period of our study, we were unable to obtain functional
outcome scores and quality-of-life scores. We had no
comparison groups so we are unable to determine if this
endoprosthesis offers advantages or disadvantages com-
pared with other prostheses or types of reconstruction.
All complications of soft tissue and instability (Hen-
derson Type 1) were managed without implant removal.
Few studies specified the incidence of complications of soft
tissue and instability; however, our results (6%) are com-
parable with those recently reported by others (7%–9%) [1,
28]. Pala et al. [28] noted that Type 1 complications were
more frequent in primary than in revision reconstructions
(10% versus 4%). Although with the numbers we had we
could not demonstrate an association between having a
previous reconstruction or an extraarticular resection, it is
plausible that soft tissue problems occur more often in
previously operated sites and after more extensive resec-
tions as a result of scarring and restricted flexibility of
surrounding soft tissues. The most common Type 1 com-
plication in a large study on KMFTR and HMRS knee
replacements (Stryker, Newbury, UK) was patellar tendon
rupture with an overall incidence of 5% [32]. We did not
observe any patellar tendon ruptures. We attribute this to
the use of the attachment tube. The tube allows for
ingrowth of the extensor apparatus and apparently ensures
reliable, long-lasting fixation [14].
Aseptic loosening (Henderson Type 2) occurred in 12%
of the primary reconstructions. This is comparable with
most long-term followup studies (Table 3). The high risk
of loosening of megaprostheses around the knee has been
ascribed to many factors, including the torque acting on the
stems and the long lever arm associated with greater
resection length [1, 35]. We could not demonstrate an
influence of resection length in the current series. HA
coating appeared to decrease the risk of loosening of
uncemented distal femoral replacements. Pala et al.
reported a comparable rate (6%) for uncemented HA-
coated GMRS prostheses (Stryker, Rutherford, NJ, USA),
although their followup was substantially shorter (Table 3).
Satisfactory rates of loosening (0%–8%) have also been
reported for cemented custom-made implants with HA
collars (Stanmore Implants Worldwide, Elstree, UK) [8,
26, 27]. Although loosening may occur as late as 25 years
after cemented fixation [19, 26, 27], it is unlikely to occur
after bony ingrowth of a HA-coated implant has taken
place [4]. A prerequisite for ingrowth is primary stability;
relative motion of more than 150 lm between bone and
stem is critical for adequate fixation [21]. Blunn et al. [4]
reported on a series of uncemented tumor implants (Stan-
more Implants Worldwide) and noted that subperiosteal
cortical bone loss occurred at the midstem level. This
process, however, stabilized, and none of their implants
was revised as a result. We did not observe this as a reason
for revision.
Like most modern tumor prostheses, the implants used
in our study had a rotating hinge (Table 3). Authors pos-
tulated that rotating hinges reduce the risk of bushing wear
and of loosening, the latter by reducing torsional stresses at
the implant-bone interface [13, 27, 28]. Myers et al. [27]
reported a reduction in loosening rates after the introduc-
tion of rotating hinges, although it is unclear whether this
reduction should be ascribed to the rotating hinge, the HA-
coated collar, or a combination of both [26]. We are of the
opinion that uncemented HA-coated implants with a
rotating hinge offer the best possibility to achieve
stable fixation and therefore durable results, although we
cannot definitively support this contention from our results.
Loosening appeared to be a particular problem in those
implants that were used as a revision of a previously failed
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reconstruction. Foo et al. [11] discussed the difficulties
encountered with the use of uncemented MUTARS1
prostheses after failed allograft reconstructions. We concur
with their conclusion that cemented fixation is preferred in
case of poor remnant bone quality as may be the case after
allograft reconstruction or loosened endoprostheses.
Structural complications (Henderson Type 3) occurred
in 15%. Introduction of the PEEK-OPTIMA1 lock has
not resulted in a reduction of long-term structural com-
plication rates. Since 2010, we routinely use the
MUTARS1 metal-on-metal locking mechanism because
we believe this mechanism should be able to better
withstand the high mechanical stresses. Our prosthetic
fracture rate (3%) is comparable with the rate reported by
Myers et al. (2%) [26] and compares favorably with other
studies (5%–7%) [2, 15, 24], whereas our followup is
among the longest reported in the literature (Table 3). All
three fractured implants had a total resection length of C
15.5 cm and two had 12-mm stems. Previously, Gosheger
et al. [13] reported stem fractures in four MUTARS1
reconstructions, all with a stem diameter of 12 mm or less.
We believe that careful reaming and implantation of the
largest possible stem diameter are advisable to reduce the
risk of stem fractures and recommend using stems of at
least 12 mm.
Infection (Henderson Type 4) occurred in 13% and
resulted in removal of the implant in 9%, which is com-
parable with most previous studies (6%–20%) [2, 15, 26–
28, 32]. We could not demonstrate a difference among
early and late infections with regard to the possibility of
implant retention. However, three late infections occurred
after operative intervention for another complication; such
infections may be treated as an acute infection as opposed
to late-occurring low-grade infections. Currently, we rou-
tinely use silver-coated implants, which may reduce the
risk of infection and increase the likelihood of being able to
retain the implant in case it gets infected [13, 36]. Others
previously reported a reduction in the frequency of infec-
tion since the routine use of muscle flaps [27].
Failure as a result of local recurrence (Type 5 compli-
cation) occurred in 7%. Other long-term followup studies
reported comparable rates (5%–6%) [3, 15, 26, 27]. Kinkel
et al. [22] noted that the rate of extraarticular resection was
substantially higher in their population (40%) compared
with other series (0%–13%; Table 3). With the numbers we
had, we found no difference in relapse or complication
risks between intra- and extraarticular resections. On the
other hand, others reported that extraarticular resection is
associated with an increased risk of infection and loosening
[13, 16]. One may therefore question whether the high rate
of extraarticular resection (46% of the primary recon-
structions in our study) is truly justified. Careful evaluation
of joint involvement with use of modern imaging
techniques (PET-CT, gadolinium-enhanced MRI) may aid
to avoid unnecessary extraarticular resections.
As a result of the fact that nearly all studies have used
Kaplan-Meier survival analyses to compute implant sur-
vival rates, and because different classifications and
definitions of failures have been used, it is difficult to
adequately compare implant failure rates. Nevertheless, our
long-term cumulative incidence rates of failure appear to
be comparable to those reported by others [1, 24, 28] and
compare favorably with others [2, 22, 26, 27] (Table 3).
Despite needing more operative procedures for com-
plications, we were able to achieve limb salvage in 90% of
our patients. The majority of our patients had a
MUTARS1 (but not necessarily the original MUTARS1
implant) in situ at latest followup, indicating that most
complications could be adequately managed.
Although no system has yet proved ideal to restore
normal function and demonstrate long-term retention of the
implant, MUTARS1 modular endoprostheses represent a
reliable long-term option for knee replacement after tumor
resection, which seems to be comparable to other modular
implants available to surgeons. The cumulative incidence
of implant failure was 20.7% at 10 years with mechanical
failure as the endpoint. Aseptic loosening was the most
important mechanical complication. HA coating of unce-
mented implants may reduce the risk of loosening, and we
currently use uncemented HA-coated implants believing
that it is optimal for durable fixation. We conclude that
MUTARS1 represents a reliable system with long-term
results comparable to other prostheses and types of
reconstructions for tumor resections about the knee.
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